Cell Based Assay & High Content Screening Markets – Customized Forecasting and Analysis 2019-2024 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell
Based Assay & High Content Screening Markets – Market Forecasts by
Application With Executive and Consultant Guides and including
Customized Forecasting and Analysis 2019 to 2024” report has
been added to ResearchAndMarkets.com’s offering.

Cell Based Assays are a mainstay of drug development and scientific
research, but growth is now accelerating as new immuno-oncology markets
create unprecedented investment in the race to cure cancer.

On top of this new technology is allowing cell based assays to be used
to measure any aspect of cell function. This market just keeps on
growing with no end in sight. The workhorse of the pharmaceutical
industry is becoming a central player in biotechnology.

This is a complex area but this readable report will bring the entire
management team up to speed, on both the technology and the opportunity.

The technology is moving faster than the market, genomics and immunology
are playing a role too. Find the opportunities and the pitfalls.
Understand growth expectations and the ultimate potential market size.

Key Topics Covered:

1. Introduction and Market Definition

1.1 What are Cell Based Assays?

1.2 Clinical Trial Failures

1.2.1 Immuno-oncology Plays a Leading Role in Cell Based Assays

1.3 Market Definition

1.3.1 Market Size

1.3.2 Currency

1.3.3 Years

1.4 Methodology

1.5 U.S. Medical Market and Pharmaceutical Research Spending –
Perspective

1.5.1 U.S. Expenditures for Pharmaceutical Research

2. Cell Based Assays – Guide to Technology

2.1 Cell Cultures

2.1.1 Cell Lines

2.1.2 Primary Cells

2.1.3 Stem Cells

2.1.3.1 iPSC’s – The Special Case

2.2 Cell Assays

2.3 Cell Viability Assays

2.4 Cell Proliferation Assays

2.5 Cytotoxicity Assays

2.6 Cell Senescence Assays

2.7 Apoptosis

2.8 Autophagy

2.9 Necrosis

2.10 Oxidative Stress

2.11 2D vs. 3D

2.12 Signalling Pathways, GPCR

2.13 Immune Regulation & Inhibition

2.14 Reporter Gene Technology

2.15 CBA Design & Development

2.16 Cell Based Assays – The Takeaway

3. Industry Overview

3.1 Players in a Dynamic Market

3.1.1 Academic Research Lab

3.1.2 Contract Research Organization

3.1.3 Genomic Instrumentation Supplier

3.1.4 Cell Line and Reagent Supplier

3.1.5 Pharmaceutical Company

3.1.6 Audit Body

3.1.7 Certification Body

4. Market Trends

4.1 Factors Driving Growth

4.1.1 Candidate Growth

4.1.2 Immuno-oncology

4.1.3 Genomic Blizzard

4.1.4 Technology Convergence

4.1.5 The Insurance Effect

4.2 Factors Limiting Growth

4.2.1 CBA Development Challenges

4.2.2 Instrument Integration

4.2.3 Protocols

4.3 Technology Development

4.3.1 3D Assays

4.3.2 Automation

4.3.3 Software

4.3.4 Primary Cells

4.3.5 Signalling and Reporter Genes

4.3.6 The Next Five Years

5. Cell Based Assays Recent Developments

5.1 Recent Developments – Importance and How to Use This Section

5.1.1 Importance of These Developments

5.1.2 How to Use This Section

• Charles River Laboratories to acquire Citoxlab
• Reaction Biology Corporation Purchases ProQinase GmbH
• Cisbio extends its assay portfolio for immuno-oncology drug discovery
• STEMCELL Technologies Launches Next-Generation Culture System
• Abcam Acquires Calico Biolabs
• Evotec announces achievement in Celgene alliance utilizing IPSC
  screening
• Fujifilm Cellular Dynamics Inc. launches iCELL Microglia
• Cisbio and Excellerate Bioscience partner
• Agilent Acquires Luxcel Biosciences
• Horizon Discovery extends CRISPR Screening Service to primary human T
  cells
• BioIVT Acquires Biological Specialty Corporation
• Miltenyi Biotec acquires microscopy specialist LaVision BioTec
• BioIVT acquires Clinical Trials Laboratory Services
• ACEA Biosciences to be Acquired by Agilent Technologies
• Olympus announces new 3D Cell Analysis technology
• Beckman Coulter Launches Flow Cytometry Software
• Agilent Technologies Inc. and BioTek Instruments, Inc to Create
  Integrated Metabolic
• Analysis and Imaging Platform
• Molecular Devices launches new features for ImageXpress Pico Automated
  Cell Imaging System
• Ncardia Launches Custom CRISPR Gene-editing in iPSC-derived Cell Lines
  with Horizon
• Discovery as Partner
• MilliporeSigma to sell Flow Cytometry Unit
• Charles River Laboratories purchases Nanion Syncropatch 384PE
• Reaction Biology and Promega announce new NanoBRET Technology
• Nanion Technologies and Ncardia to enhance Options for Cardiac
  Researchers
• Citoxlab signs deal with Experimental Pharmacology and Oncology
  Berlin-Buch GmbH (EPO)
• Battery Ventures Acquires TTP Labtech Limited
• BD Launches Cell Sorter to Enable Sorting of Rare Cell Types
• Enzo Life Sciences Introduces Validated Antibodies for IHC
• Sartorius launches new high throughput bioreactor system

6. Profiles of Key Cell Based Assay Companies

• Abcam
• Agilent
• Beckman Coulter, Inc.
• Becton Dickinson
• BioIVT
• Bio-Rad Laboratories, Inc.
• BioTek Instruments
• BioVision, Inc.
• Cell Biolabs, Inc.
• Cell Signaling Technology, Inc.
• Charles River Laboratories, Inc.
• Cisbio Bioassays
• Corning, Inc
• Cytovale
• Enzo Life Sciences, Inc
• Eurofins DiscoverX Corporation
• Evotec AG
• Excellerate Bioscience
• Fujifilm Cellular Dynamics International
• GE Healthcare Life Sciences
• Hemogenix
• Horizon Discovery Group plc
• Invivogen
• Leica Biosystems
• Lonza Group Ltd.
• Merck KgaA
• Miltenyi Biotec
• Molecular Devices
• Nanion
• Ncardia
• New England Biolabs, Inc.
• Olympus
• Origene Technologies
• PerkinElmer, Inc.
• Promega Corporation
• Qiagen NV
• Reaction Biology
• Roche Group
• Sartorius
• Sony Biotechnology
• Stemcells Technologies Canada Inc
• Thermo Fisher Scientific, Inc.
• TTP Labtech
• Vitro Biopharma

7. Global Market Size

8. Global Market by User Type

8.1 Pharmaceutical Market

8.2 Basic Research Market

8.3 Industrial/Cosmetic Market

9. Cell Based Assay by Product Class

9.1 Instrument Market

9.2 Reagent Market

9.3 Services Market

9.4 Software Market

10. Appendices

10.1 FDA Cancer Drug Approvals by Year

10.2 Clinical Trials Started 2010 to 2016

10.3 Share of Pharma R&D by Country

For more information about this report visit https://www.researchandmarkets.com/r/1ch2tg

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology,
Drug
Discovery